BREXPIPRAZOLE (Rexulti ®)
LPT prescribing group have reviewed and found no significant advantages over existing formulary products
Date of classification
Do not prescribe
Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.